Synthesis of the cardiac inotropic polypeptide anthopleurin-A.
M W Pennington, I Zadenberg, M E Byrnes, R S Norton, W R Kem
Index: Int. J. Pept. Protein Res. 43(5) , 463-70, (1994)
Full Text: HTML
Abstract
The sea anemone polypeptide anthopleurin-A (AP-A) at nanomolar concentrations enhances myocardial contractility without affecting automaticity. It has a therapeutic index higher than that of the digitalis glycosides, and may serve as a molecular model for designing a new class of inotropic drugs acting on the myocardial Na channel at site 3. AP-A is a 49 residue peptide crosslinked by three disulfide bonds; its tertiary structure has been determined by NMR. Here we report the solid-phase synthesis of this polypeptide. Synthetic AP-A displayed CD and NMR spectra identical with those of the natural toxin; it possessed 94 +/- 15% of the inotropic activity of natural AP-A. Therefore, it is feasible to prepare various type 1 sea anemone toxin analogs by solid-phase chemical synthesis in order to identify side chains important for peptide folding and interaction with sodium channels.
Related Compounds
Related Articles:
Chemical modification of cationic groups in the polypeptide cardiac stimulant anthopleurin-A.
1995-02-01
[Toxicon 33(2) , 187-99, (1995)]
Spatial dispersion of repolarization is a key factor in the arrhythmogenicity of long QT syndrome.
2004-03-01
[J. Cardiovasc. Electrophysiol. 15(3) , 323-31, (2004)]
Three-dimensional structure in solution of the polypeptide cardiac stimulant anthopleurin-A.
1995-03-21
[Biochemistry 34(11) , 3782-94, (1995)]
2002-06-01
[Biophys. J. 82(6) , 3048-55, (2002)]
Enhancement of closed-state inactivation in long QT syndrome sodium channel mutation DeltaKPQ.
2002-09-01
[Am. J. Physiol. Heart Circ. Physiol. 283(3) , H966-75, (2002)]